Inve US ▾

TG Therapeutics (TGTX) earnings

TG THERAPEUTICS, INC.· Health Care

Results to
Jun 2026
Latest analysed call
Jun 2026 (Q2 FY26)
Balance sheet to
Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

TG Therapeutics earnings: last reported Mon, 3 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue240 $ million+70.3% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin9.0 %−15.7 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit7.8 $ million−72.4% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Guidance

What management said, and what became of it

17 of 18 judged targets kept · 12 open · verdicts reflect calls analysed to Jun 2026.

TG THERAPEUTICS, INC. management guidance track record: 30 targets tracked across analysed earnings calls (17 achieved, 1 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
BRIUMVI subcutaneous Phase I PK/bioequivalence data presentationlater this yearMar 2025Jun 2026:We reported positive Phase I bioavailability data for our proprietary subcutaneous formulation, increasing our confidence in the quarterly dosing schedule
Call transcript, Jun 2026 · no direct link		Achieved*
30-minute BRIUMVI infusion pivotal trial initiationgetting going later in the year or early next yearMar 2025No later analysed call mentions it.Pending
Full-year 2026 BRIUMVI U.S. net product revenue guidance$825 million to $850 millionDec 2025Jun 2026:we're raising our full year U.S. BRIUMVI net revenue guidance to $890 million to $905 million and now expect approximately $950 million in total global revenue for 2026
Call transcript, Jun 2026 · no direct link		Revised Up

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of TG THERAPEUTICS, INC.'s 30 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 27 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. US Pro opens 100 a month: first month free, no card.
See the full record

Price

$53.3 −1.24% · −$0.67

Last close Oct 19, 2026 · US · USD

Performance +53.7% 1Y

$30.0$40.0$50.0$60.0Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Aug 26Oct 26Dec 2025 (Q4 FY25) — 26 Feb 2026Mar 2026 (Q1 FY26) — 6 May 2026Jun 2026 (Q2 FY26) — 3 Aug 2026

1Y: $34.67 on 17 Oct 2025 → $53.3. High $59.06 (9 Jul 2026), low $26.94 (12 Mar 2026).

Previous close
$53.97
52-week range
$26.94 – $59.06
One year
+51.77%

Overview

Symbol
TGTX
Exchange
US
Currency
USD

Your own record

Start an Inve Case for TG THERAPEUTICS, INC.

Free account. Everything above stays public.

Write why you follow TG THERAPEUTICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other US companies filed under T

All 170 companies under T

US companies A–Z · Earnings calls · US earnings-call directory · US sector analysis · What management promised, and delivered